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Background: Mutation analysis of proto-oncogene c-kit (c-kit) is advisable before starting treatment with tyrosine
kinase inhibitors in dogs with mast cell tumor (MCT), including those with metastatic disease. Testing is usually performed
on primary tumors, assuming that c-kit mutation status does not change in metastasis.
Hypothesis/Objectives: To give an insight into the mutational processes and to make a recommendation on the use of
c-kit mutational analysis in the clinical setting.
Animals: Twenty-one client-owned dogs with metastatic MCT.
Methods: Dogs undergoing resection or biopsy for both primary and matched metastatic MCT were prospectively
enrolled. Total RNA or DNA was extracted from primary MCT and corresponding metastases. Exons 8, 9, and 11 were
amplified by PCR and sequenced. Genetic features between primary MCT and metastases were compared. Their correla-
tion with clinicopathologic features was investigated.
Results: Concordance (mutated or wild-type) of mutational status, evaluable in 21 primary and matched metastatic (20
nodal and 1 splenic) MCTs, was 100%. Three new c-kit mutations were identified. No significant correlation was detected
between c-kit mutation and clinicopathologic features.
Conclusions and Clinical Importance: Proto-oncogene c-kit mutational status is conserved between any primary and its
matched secondary tumor, suggesting that both can be used for c-kit mutational testing. Targeted therapies might be also
used to treat metastatic disease.
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The proto-oncogene c-kit (c-kit), which encodes forthe transmembrane receptor KIT, is known to
play a critical role in mast cell development and
tumors.1 In dogs, approximately 9–30% of mast cell
tumors (MCTs) show c-kit mutations, including inter-
nal tandem duplications (ITDs) in the juxtamembrane
domain, resulting in constitutive activation of KIT in
the absence of ligand binding,1,2 and activating point
mutations in c-kit extracellular domains (eg, exons 8
and 9).3 In general, ITDs are associated with an
increased risk of metastasis and local recurrence,
higher tumor proliferation index, and aberrant KIT
localization.2,4–6
The importance of the mutational status has been
elucidated by 2 clinical trials, which showed a lower
objective response rate and a shorter survival time
when tyrosine kinase inhibitors (TKIs) including to-
ceranib and masitinib, respectively, were administered
to dogs with wild-type (WT) tumors.7,8 Although TKI-
based therapy is used in dogs with MCT to also treat
metastatic disease in the lymph nodes,7 c-kit status is
generally evaluated in the primary lesions because met-
astatic sites are rarely removed or biopsied before
treatment. However, it is still unknown whether c-kit
status differs in metastases compared with primary
tumors. The rationale for using small molecule inhibi-
tors of oncogenic proteins as cancer therapies depends,
at least in part, on the assumption that metastatic
tumors are primarily clonal with respect to the mutant
oncogene. If this is not the case, targeted therapies
might only be partially efficacious. Therefore, it is of
primary importance to verify the correlation between
primaries and related metastases with regard to c-kit
status.
In people, controversy exists regarding the stability
of mutational status in various tumors throughout the
course of the disease, leading to metastases with differ-
ent mutational status from that of the primary
tumor.9–11 In veterinary medicine, there are only 2
studies comparing immunohistochemical phenotypes
between primary mammary carcinomas and their
related lymph node metastasis.12,13 In cats, concor-
dance between primary mammary carcinoma and
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matched metastasis was detected in 57.1% of cases,12
whereas in dogs in 65% of cases.13
To the authors’ knowledge, very few studies have
been conducted in dogs on the rate of concordance in
terms of c-kit mutations. One study showed c-kit ITD
heterogeneity in different sites of multiple MCTs in 2
dogs14; in another study, c-kit ITDs were used to pro-
vide evidence of tumor clonality in multiple MCTs
developing over 1–2 years in 2 dogs.15
In this study, we prospectively analyzed matched
primary and metastatic MCT specimens for c-kit intra-
and intertumor heterogeneity (1) to give an insight into
the mutational processes; and (2) to make a recom-
mendation on the use of c-kit mutational analysis in
the clinical setting. Moreover, the treatment with TKIs
is associated with potential toxicity and high costs;
additionally, resistance to certain TKIs is often caused
by secondary mutations of c-kit7,16; therefore, it is
important to critically review all aspects of the muta-
tional testing to enhance upfront patient selection.
We hypothesized a discordance of c-kit mutational
status between matched primary and metastatic MCT,
thereby recommending the use of c-kit mutational test-
ing on all involved sites.
Materials and Methods
Case Selection and Tumor Specimens
Inclusion Criteria. Dogs with histologically confirmed MCT
undergoing complete clinical staging and total or partial surgical
excision of the primary tumor and corresponding metastasis were
prospectively recruited. Treatment with neoadjuvant medical
treatment (including steroids, chemotherapy, targeted therapy)
was not permitted.
Background information recorded for each dog included sig-
nalment, body weight, and primary tumor description (location,
dimension, presence of ulceration, grade according to Patnaik
and Kiupel’s sytems).17 Initial staging included history and phys-
ical examination, complete blood cell count with differential,
serum biochemistry, coagulation profile, cytological evaluation of
the cutaneous nodule and regional lymph node, thoracic radio-
graphs (3 views), abdominal ultrasound, fine-needle aspirates of
liver and spleen regardless of their sonographic appearance, and
cytologic examination of bone marrow obtained from the iliac
crest. Lymph nodes or viscera were considered metastatic, if
mast cells appeared in clusters or sheets, in very large numbers
or atypical on morphology, as previously documented.18 Histo-
logically, nodal metastatic spread was supported by the localiza-
tion of mast cells in the subcapsular sinuses; special
histochemical stains (Giemsa) were used to detect poorly granu-
lated mast cells. Written informed consent was obtained from all
owners.
Tumor Specimens. Tumor samples were obtained by partial
or total surgical resection from each primary MCT and
matched metastasis before starting any medical treatment. To
formulate a histologic diagnosis, samples were fixed in 10%
buffered formalin, processed, and embedded in paraffin using a
standardized protocol. Slides were reviewed by a single board-
certified pathologist (SDP), and histopathologic criteria for
diagnosis were based on those previously published for canine
MCT.19,20
With regard to c-kit sequencing analysis, either 1 tissue core
(2-mm diameter) or fine-needle aspirates (FNA) were obtained
from each primary MCT sample and matched metastases.
Specimens were submersed in a stabilization and storage solution
(RNAlater Solutiona ) and refrigerated at 20°C until use.
Whenever the primary tumor was surgically excised by other vet-
erinarians, 10-lm sections of the corresponding formalin-fixed
and paraffin-embedded (FFPE) block were used for nucleic acid
extraction.
Molecular Analysis
Nucleic Acid Extraction. Total RNA was extracted from biop-
sies and FNA21 with a nucleic acid isolation reagentb and a com-
mercial kit (High Pure RNA Isolation Kitc), respectively,
according to the manufacturer’s instructions. Whenever nucleic
acids were extracted from FFPE primary tumor sections, another
commercial kitd was used. In this case, the genomic DNA was
preferred to RNA because of the poor quality of the extracted
RNA.
Nucleic acids yield and purity (260/280 and 260/230 nm absor-
bance ratios) were measured with a spectrophotometer,e while
their quality was checked by 1% agarose gel electrophoresis.
Two micrograms of total RNA was reverse transcribed with a
commercial kit (High Capacity cDNA Reverse Transcription
Kita). Both cDNA and DNA were finally stored at 20°C until
use.
c-kit Genotyping. Exons 8, 9, and 11, considered the hot spot
regions for activating protein mutations, were screened by PCR
and direct sequencing.3,22 To amplify either c-kit exons 8, 9,
and 11 (starting from cDNA) or exon 11 (from DNA), previ-
ously published primers pairs and PCR conditions were used.23
Conversely, exons 8 and 9 primers for genomic DNA amplifi-
cation were designed ex novo,f and forward and reverse primers
as well as the expected amplicon sizes are reported in Table 1.
Amplifications were carried out in a thermocycler,g with a com-
mercially available PCR kit.h Two microliters of 5-fold diluted
DNA was used as template, while primeri concentrations were
16.5 pmol each. Amplicons were visualized in 1.5% agarose
gel.
Whenever the presence of additional bands of different
length (roughly 30 bp) was noticed, these ones were at first
individually excised from the agarose gel and, then, purified
with a commercial kit (High Pure PCR Cleanup Micro Kitc),
according to the manufacturer’s instructions. Hence, PCR prod-
ucts were sequenced, using the same PCR primers, with either
a capillary electrophoresis machine (ABI Prism 3100 Genetic
Analyzera) or an automatic sequencer (ABI 3730XL DNA
Analyzera).
Sequences were analyzed by a commercially available soft-
ware.j Alignments with the WT c-kit mRNA sequence
NM_001003181.1, to discover potential single nucleotide poly-
morphisms (SNPs), ITDs, or deletions, were performed by an
open source software.k
Table 1. Primers for genomic DNA amplification and
sequencing of c-kit exons 8 and 9.




8 F: ACTCACTGGTTCCGATGCTC 408
R: CCCTTAAAAAGCCACATGGA
9 F: CACCCTTGGTTGAAAAAGGA 458
R: ATATGGCAGGCAGAGCCTAA
bp, base pairs; F, forward; R, reverse.
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Treatment and Response Criteria
The type of treatment was at the investigator’s personal discre-
tion, and included surgery, radiation therapy, chemotherapy,
TKI, or a combination of these. Response was determined by
RECIST criteria.24 Briefly, disappearance of all lesions was
defined as complete response (CR); a decrease of at least 30% in
the diameter of a lesion was defined as partial response (PR); the
appearance of new MCTs or at least a 20% increase in the diam-
eter of a lesion was defined as progressive disease (PD); <30%
reduction or 20% increase in the diameter of a lesion was defined
as stable disease (SD).
Statistical Analysis
To evaluate the relationship between c-kit mutations and clini-
copathologic factors, data were analyzed by Fisher’s exact test
and Pearson v2 test. For this purpose, the following clinicopatho-
logic features were taken into account: sex (male or female), repro-
ductive status (intact or neutered), breed (purebred or crossbred;
predisposition to biologically aggressive MCTs [meaning advanced
grade or clinical stage], eg, Shar-Pei and Labrador Retriever), age
(< or ≥10 years), weight (< or ≥10 kg), dimension of the primary
lesion (< or ≥3 cm), clinical stage (II or III or IV), substage (a or
b), and histologic grading (both Patnaik and Kiupel’s sys-
tems).17,25–28 The anatomic site was categorized as benign or
malignant, as some locations have been described as biologically
aggressive (eg, inguinal/perineal, head and neck, digit).17 Survival
time was defined as the time interval between the initiation of
treatment and death. Dogs dead from disease or MCT-related
causes were classified as events; those dead for unrelated causes or
lost to follow-up at the time of the study closure were censored.
Statistical calculations were performed by a commercial soft-
ware package.l For all statistical analysis, significance was set at
P < .05.
Results
Dogs and MCT Demographics
Between July 2011 and August 2013, 21 dogs met
the inclusion criteria and were enrolled. There were 6
Labrador Retrievers, 5 crossbred dogs, 3 Boxers, and
one each of the following: Breton, Shih-Tzu, Shar-Pei,
Beagle, American Staffordshire Terrier, German
Hound, and Dogue de Bordeaux. Twelve dogs were
spayed females, 3 intact females, 4 intact males, and 2
castrated males. Median age was 8 years (range, 3–
14 years), and median body weight was 26.7 kg (range
7.4–50.2 kg).
Eighteen (86%) dogs had single lesions, and 3
(14%) had concurrent multiple tumors. In these latter
ones, the biggest MCT was sampled for both histo-
pathologic and mutational analysis. MCTs were in
various locations, including 6 (29%) dogs with tumors
on distal limbs; 4 (19%) dogs with their tumors on the
head; 3 (14%) dogs with digital MCTs; 2 (10%) dogs
with tumors on proximal limbs; 2 (10%) dogs with
vulvar tumors; and 1 (5%) dog with a MCT on the
abdominal wall. All dogs with multiple tumors had
them in the same regional areas (axillary region, head,
and abdominal wall).
Histopathology was available for all primary MCTs:
14 (66%) dogs had Patnaik’s grade 2 MCTs, 6 (29%)
dogs had grade 3 MCTs, and 1 (5%) dog had a grade
1 MCT. Regarding the Kiupel’s grading system, 11
(52%) tumors were classified as low-grade MCTs and
10 (48%) as high-grade MCTs.
All dogs had metastatic disease: 20 (95%) dogs
had regional lymph node involvement and, among
these; 2 also had hepatic metastasis; 2 had splenic
and hepatic metastasis; 1 had hepatic, splenic, and
marrow metastasis; 1 had splenic metastasis; and 1
had cutaneous metastasis. One (5%) dog had
involvement of liver and spleen without regional
lymph node metastasis. Lymph node metastases were
confirmed in all 20 dogs by means of histopathol-
ogy; the remaining dog without lymph node metasta-
sis had only cytologic diagnosis of liver and spleen
involvement.
Overall, 11 (52%) dogs had stage II disease; 8
(38%) dogs had stage IV disease; and 2 (10%) dogs
had stage III disease. Sixteen (76%) dogs were asymp-
tomatic (substage a), and 5 (24%) dogs had signs of
systemic effects of MCT (vomiting, diarrhea, pruritus,
and regional edema).
c-kit Mutation Status
All specimens of primary tumors and paired metas-
tases were suitable for c-kit genotyping. Mutations of
c-kit sequence were detected in 3 (14%) MCTs: 1 in
exon 8 (Fig 1); and 2 in exon 11 (Fig 2). Two of them
were noticed in dogs with grade 3 MCTs, and 1 in a
dog with a grade 2 MCT.
A new 28 amino acids (AAs) deletion affecting 10 AA
codons, namely from Histidine-421 (H421) to Gluta-
mine-430 (Q430), coupled with a contemporary insertion
of 10 base pairs (bp) coding for four AAs (Leucine-
Threonine-Phenylalanine-Methionine, LTFM), was
detected in exon 8 (Fig 1). This mutation was named
1262_1289delinsTGACTTTCAT, in agreement with the
nomenclature for human sequence variations.29 More-
over, 2 new ITDs were found in exon 11 (Fig 2): a first
one, consisting in the insertion of 12 AAs at the residue
571 (ITD571–582); and a second one based on an addition
of 14 AAs at the residue 574 (ITD574–587).
Furthermore, 2 already known silent SNPs were
detected in exon 8 (1275G > A)3 and in exon 11
(1759C > T).30 The relative frequencies were 33%
(7/21) and 5% (1/21), respectively.
Noteworthy, the comparison of c-kit mutations and
SNPs in primary tumors and corresponding metastases
showed a concordance rate of 100%. Likewise, all
dogs with a primary WT c-kit genotype showed a WT
c-kit in their matched metastases.
Treatment and Clinical Follow-up
Eleven (52%) dogs (including the 3 dogs with c-kit
mutation) underwent surgical excision of their MCT.
Four of these animals also received systemic chemo-
therapy (vinblastine and prednisone) as front-line
treatment; 3 dogs received vinblastine and TKIs; 1 dog
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was treated with curative radiation therapy and TKIs;
and one with curative radiation therapy and vinblas-
tine. Two (10%) dogs received systemic chemotherapy
(vinblastine and prednisone) as their only treatment.
Six (28%) dogs were treated with palliative radiation
therapy; 4 of these 6 also received vinblastine and
prednisone, and 4 other ones TKI. Finally, 2 (10%)
dogs were only treated with TKIs.
Overall, 11 (52%) dogs achieved CR, 7 (33%)
dogs PR, 2 (10%) dogs SD, whereas 1 (5%) dog did
not respond to the treatment and experienced PD.
At the end of the study, 10 (48%) dogs were still
alive with a median follow-up of 205 days (range 41–
473 days), and 11 (52%) dogs died or were eutha-
nized because of progression of their MCT (n = 10)
or for tumor-unrelated causes (n = 1). The overall
median survival was 51 and 149 days for dogs har-
boring c-kit mutations and with WT c-kit gene,
respectively.
Relationship between c-kit Mutational Status and
Clinicopathologic Features
No significant correlation was found between pri-
mary c-kit mutation and the considered clinicopatho-
logic characteristics (Table 2).
Fig 1. Direct sequencing of c-kit exon 8 from canine mast cell tumors. Both wild-type and mutated nucleotide and protein alignments
sequences are reported. In cDNA obtained from primary tumor and matched metastasis (the corresponding lymph node), a deletion of
10 amino acids (AAs) (HESLTNGMLQ), associated with an insertion of 4 AAs (Leucine-Threonine-Phenylalanine-Methionine), was
detected. This new c-kit mutation was termed 1262_1289delinsTGACTTTCAT, according to the nomenclature for human sequence vari-
ations.25
Fig 2. Direct sequencing of mutant c-kit exon 11 from canine mast cell tumors. Alignments of both wild-type and mutated protein
sequences are reported. Two internal tandem duplications (ITDs), namely (A) ITD571-582 and (B) ITD574-587, were detected in cDNA
obtained from primary tumor and matched metastasis (the corresponding lymph node).
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Discussion
In this study, we compared c-kit mutational status of
exons 8, 9, and 11 between primary MCT and matched
metastasis, and found a perfect (100%) concordance.
Metastatic MCT represents a major health problem
in the canine population, but the introduction of a
novel class of targeted antineoplastic agents directed
against KIT, TKI, has significantly changed the thera-
peutic options available for these dogs.7,8 Indeed, the
important role of targeted therapy against molecules
contributing to tumor development, progression, and
metastasis has attracted considerable attention.31
Because the identification of the mutational status of
c-kit could help to select dogs that have a high
probability of benefiting from TKI,7 it is of primary
importance to verify the degree of correlation between
primaries and related metastases with regard to c-kit
status. Indeed, mutations are mainly evaluated at the
primary site and there are little data available regard-
ing the possible concordance in mutational status
between the primary tumor and the corresponding
metastases.7,8 However, the death of metastatic cells is
the main goal of treatment in a metastatic setting.
These cells might be biologically different from the pri-
mary tumor, which has implications for the clinical
management of MCT.
It is well known that the progression of cancer
develops from a single mutated cell, followed by malig-
nant clonal expansion secondary to additional genetic
and genomic alterations. As a consequence, the ongo-
ing acquisition of these alterations can result in the
emergence of neoplastic subclones with varying geno-
types and, consequently, phenotypes,32 leading to
discordance between the primary tumor and its
metastases. In people, several tumors including mela-
noma,33 gastrointestinal stromal tumor,34 and lung
cancer35 show intratumor and intertumor heterogene-
ity, indicating the presence of more than one clone of
cancer cells within a given neoplastic mass, and the
presence of different genetic alterations in different
metastatic sites from a single patient, respectively.
Therefore, determining if there is homogeneous muta-
tional status between primary tumor and its metastatic
sites has important clinical implications, overall to
select the appropriate treatment. To our knowledge,
the question of mutational status in metastases versus
primary MCT has not been addressed so far.
Compared to previously published studies, the muta-
tional status of our case series, including both primary
and secondary metastatic tumors, showed a similar
proportion of c-kit mutations.23 Two already known
SNPs were found in exon 8 and 113,30; furthermore, 3
novel mutations (1 in exon 8 and 2 in exon 11), with
unknown clinical relevance, were found.
The data presented in this study provide evidence
that the WT or mutated c-kit genotype is conserved in
primary MCTs and their matched, concurrent metasta-
ses. Although a similar behavior has been reported in
human melanomas,22 this result is somewhat surpris-
ing, in the light of genomic instability and heterogene-
ity that characterize most malignant tumors. In fact, it
is generally accepted as true that loss of primary muta-
tion, gain of secondary mutation, or both might occur
in patients regardless of the use chemotherapy or tar-
geted therapy; such a phenomenon can be explained
by the fact that cells with different mutations coexist
within the primary tumor, and clonal selection for
mutations during tumor progression might lead to dif-
ferent c-kit mutations status in metastatic sites from
that of the primary tumors.14,36
In the present analysis, discordant cases were not
observed, pointing out that in canine MCTs, c-kit sta-
tus is maintained in all cases unchanged during the
metastatic process.
Another question, still matter of debate, is whether
activating c-kit mutations might be related to a poor
Table 2. Relationship between c-kit mutational status






<10 2 9 1.000a
>10 1 9
Sex
Male 2 4 .184a
Female 1 14
Breed
Pure breed 3 13 .549a
Crossbred 0 5
Breed predisposition to aggressive MCTs
Yes 2 5 .247a
No 1 13
Weight (kg)
<10 1 1 .271a
>10 2 17
Primary lesion, anatomic site
Benign 0 11 .090a
Malignant 3 7
Primary lesion, dimension (cm)
<3 1 9 1.000a
>3 2 9
Metastatic lymph node
Yes 3 17 1.000a
No 0 1
Stage




a 1 15 .128a
b 2 3
Histologic grade (Patnaik)
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prognosis in canine MCTs.23,37 Based on our results,
dogs with c-kit mutations had a shorter survival time
when compared with dogs with WT MCTs. However,
because of the different treatments and the limited
number of mutated cases, conclusions on the prognos-
tic relevance of c-kit mutations cannot be drawn. Also,
a number of variables, including sex, reproductive
status, breed, age, weight, dimension of the primary
lesion, clinical stage, substage, and histologic grading,
were evaluated to determine whether they were corre-
lated with c-kit status. None of these variables was
found to be significantly associated with the presence
of c-kit mutations, although the small population
might have led to an insufficient power to detect differ-
ences between subgroups.
Although the current report is limited by the small
sample size, our observations indicate that c-kit muta-
tion in the primary tumors might predict c-kit mutated
metastases with a reasonably high probability, suggest-
ing that c-kit mutation represents a very early muta-
tional step in MCT pathogenesis and plays a central
role in tumor progression. The implication of these
results for general oncology practice is that both tis-
sues of primary tumor or metastasis can be used for c-
kit mutation testing. However, the low number of
mutated cases analyzed at the present time does not
allow drawing any definitive conclusions about the c-
kit asset in synchronous and metachronous metastases,
as well as their association with response to treatment.
Clearly, further molecular studies, carried out on
dogs with metastatic MCT and receiving chemother-
apy, TKI, or both, are needed to clarify whether c-kit
genotype might be somewhat affected by anticancer
drugs.
Finally, it must be stressed that the results of our
study are valid for lymph node metastases and cannot
be extrapolated to other metastatic locations, as only 1
dog with splenic involvement was evaluated here. The
lymph node is the predominant site of metastases in
the majority of dogs with metastatic MCT; therefore,
the results of our study of 20 lymph node metastases
provide a reference for clinical decision-making as to
TKI therapy. Nevertheless, as the molecular patterns
might differ between metastatic sites,14,38 and because
c-kit secondary mutations are likely to occur after
TKIs administration,16,39,40 more results need to be
obtained by testing additional metastatic sites, includ-
ing spleen and liver, before and after targeted thera-
pies. Also, the identification of new c-kit ITDs
underscores the need of further molecular investiga-
tions on their prognostic significance.
In conclusion, the mutational status seems to be sta-
ble during MCT metastasis, which is encouraging for
TKI use in the clinical setting.
Footnotes
a Life Technologies, Foster City, CA
b TRIzol Reagent; Applied Biosystems, Foster City, CA
c Roche Applied Science, Indianapolis, IN
d AllPrep DNA/RNA FFPE kit, Qiagen, Milan, Italy
e Nanodrop ND-1000 Spectrophotometer, Nanodrop Technolo-
gies, Wilmington, UK
f Primer3 software, http://primer3.sourceforge.net
g TPersonal, Biometra GmbH, Goettingen, Germany
h GoTaq Flexi DNA polymerase; Promega Corp., Madison, WI
i Eurofins MWG Operon, Ebersberg, Germany
j FinchTV Software, Geospiza Inc., Seattle, WA
k Multalin, http://multalin.toulouse.inra.fr/multalin
l GraphPad Prism 5, San Diego, CA
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